Correlation between MIB-1 and other proliferation markers: Clinical implications of the MIB-1 cutoff value

Cancer

Volumn 94, Issue 8, 2002, Pages 2151-2159

  Spyratos, Frédérique ^a   Ferrero Poüs, Magali ^a   Trassard, Martine ^a   Hacéne, Kamel ^a   Phillips, Edelmira ^a   Tubiana Hulin, Michèle ^a   Le Doussal, Viviane ^a  

^a CENTRE RENÉ HUGUENIN   (France)

Author keywords

Breast carcinoma; Cutoff; MIB 1; Proliferation

Indexed keywords

DNA; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY KI 67; PROGESTERONE RECEPTOR; THYMIDINE KINASE;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL CYCLE S PHASE; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENECTOMY; MITOSIS; PRIORITY JOURNAL; TUMOR CLASSIFICATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NUCLEAR; BIOPSY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL DIVISION; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MIDDLE AGED; MITOTIC INDEX; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0037089663     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10458     Document Type: Article

References (34)

1. New prognostic factors for breast cancer recurrence
2. Histological and prognosis in breast carcinomas
3. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas
4. Method for grading breast cancer
5. Cell proliferation in 3,800 node-negative breast cancers: Consistency over time of biological and clinical information provided by 3H-thymidine labelling index
6. S-phase fraction and breast cancer - A decade of experience
7. Thymidine kinase as a proliferative marker: Clinical relevance in 1,692 primary breast cancer patients
8. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67
9. The Ki-67 protein: From the known and the unknown
10. New Ki- 67- equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope
11. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections
12. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999
13. American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
14. S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: A standardized flow cytometric study
15. Prognostic of DNA- synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, MO breast cancers: A retrospective multicenter study
16. EORTC receptor and biomarker study group report analytical and technical evaluation of a thymidine kinase radio-enzymatic assay in breast cancer cytosols
17. Flow cytometry in node-positive breast cancer: Cancer and leukemia group B protocol 8869
18. S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer
19. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: Results from the Eastern Cooperative Oncology Group Companion Study, EST 4189
20. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer
21. Intratumoural heterogeneity of proliferation in invasive breast carcinoma evaluated with MIB1 antibody
22. Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer
23. Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas
24. MIB-1 labeling index is an independent prognostic marker in primary breast cancer
25. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1
26. Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma
27. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer
28. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer
29. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody
30. Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy, tumor regression, and short-term follow-up
31. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy
32. Correlation among MIB-1, paraffin section proliferation index, and recurrence in low-stage breast carcinoma
33. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
34. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays